NXL-001
Alzheimer's Disease
Key Facts
About NeuExcell Therapeutics
NeuExcell Therapeutics is a private, clinical-stage biotech based in Philadelphia, developing a transformative gene therapy platform for neural repair. Its core technology, the ATN platform, aims to regenerate functional neurons in vivo by reprogramming astrocytes, offering a potential disease-modifying approach for a broad range of neurological conditions. With three active clinical trials, over $25 million in disclosed funding, and a strong scientific foundation from founder Dr. Gong Chen, the company is positioned as a leader in the nascent field of direct neural reprogramming.
View full company profileAbout NeuExcell Therapeutics
NeuExcell Therapeutics is a private, clinical-stage biotech based in Philadelphia, developing a transformative gene therapy platform for neural repair. Its core technology, the ATN platform, aims to regenerate functional neurons in vivo by reprogramming astrocytes, offering a potential disease-modifying approach for a broad range of neurological conditions. With three active clinical trials, over $25 million in disclosed funding, and a strong scientific foundation from founder Dr. Gong Chen, the company is positioned as a leader in the nascent field of direct neural reprogramming.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| ALZN002 | Alzamend Neuro | Preclinical |
| P021 | Phanes Biotech | Preclinical |
| PB43D | Phanes Biotech | Preclinical |
| UB-311 | Vaxxinity | Phase 2 |
| Lecanemab | BioArctic | Launched |
| BAN2401 | BioArctic | Preclinical |
| Undisclosed Programs | johnson-and-johnson-innovative-medicine | Pipeline |
| MK-6240 (florquinitau) | Lantheus Medical Imaging | Regulatory Filing |
| NAV-4694 (flutafuranol) | Lantheus Medical Imaging | Phase 3 |
| LNTH-2620/PI-2620 | Lantheus Medical Imaging | Phase 3 |
| itMSCs | Stemedica Cell Technologies | Clinical Development |